LAS VEGAS — In this Healio Video Perspective from Clinical Trials at the Summit, Arshad M. Khanani, MD, MA, FASRS, highlights first-time results of PER-001 intravitreal implant in diabetic retinopathy.
PER-001 (Perfuse Therapeutics), an endothelin antagonist, was delivered at low and high doses and compared with control, showing structure improvements in macular ischemia, leakage and microaneurysms. Additionally, in a glaucoma program, patients experienced improved OCT retinal nerve fiber layer and blood flow to the optic nerve.
“In terms of function, we actually saw improvement in